GlassScriptPhysician profile
Robert B Houska
NPI 1740216373
$1,838.61
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $336.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $331.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $295.17 | 2019-2020 | |
| Amgen INC. | $176.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $166.95 | 2019-2020 | |
| Pfizer INC. | $146.13 | 2019-2020 | |
| Lilly USA, LLC | $83.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $77.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.71 | 2019 | |
| Allergan, INC. | $56.16 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.65 | 2019-2020 | |
| Genentech USA, INC. | $47.76 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $36.61 | 2019-2020 | |
| Amarin Pharma, INC. | $36.17 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.07 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.19 | 2019 | |
| Shire North American Group INC | $16.82 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.65 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.69 | 2019 | |
| Mylan Specialty L.P. | $12.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Houska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.